<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470352</url>
  </required_header>
  <id_info>
    <org_study_id>Migrain-0265-11CTIL</org_study_id>
    <nct_id>NCT01470352</nct_id>
  </id_info>
  <brief_title>Multiparametric MRI Study of Endogenous Analgesia and Prediction the Efficacy of Migraine Pharmacological Prevention</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>d_yarnitsky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To delineate brain mechanisms that subserve EA in the healthy state and to identify&#xD;
      alterations in mechanisms supporting EA in chronic pain and their therapeutic relevance.&#xD;
      Individuals with migraine will be examined between episodes in order to assess basal&#xD;
      alterations in the efficiency of spatial and temporal filtering of noxious information. This&#xD;
      population provides the unique opportunity to examine such processes without confounds&#xD;
      arising from ongoing pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain is a uniquely individual experience that is powerfully shaped by the action of&#xD;
      descending control mechanisms. These systems may play crucial roles in the moment-to-moment&#xD;
      tuning of the sensitivity, spatial, and temporal response characteristics of nociceptive&#xD;
      processing mechanisms during both acute and pathological pain states. However, these systems&#xD;
      remain poorly understood in human subjects. The proposed research will use psychophysics and&#xD;
      multiparametric MRI to (i) delineate the brain mechanisms that subserve and regulate&#xD;
      endogenous analgesia (EA) in the healthy state and (ii) to identify alterations in mechanisms&#xD;
      supporting EA in chronic pain and their therapeutic relevance. In both healthy subjects and&#xD;
      chronic pain patients, EA will be probed using the DNIC (diffuse noxious inhibitory controls)&#xD;
      and offset analgesia paradigms. Functional MRI will examine activation of brainstem&#xD;
      mechanisms important in EA, while both functional and structural connectivity analyses will&#xD;
      assess the regulation of these brainstem mechanisms by cerebral cortical regions involved in&#xD;
      attention and affect. One pathological painful condition, migraine, will be examined since it&#xD;
      allows changes in EA associated with chronic pain to be investigated between episodes of&#xD;
      pain. Finally, EA and EA associated structural and functional parameters will be used to&#xD;
      predict the efficacy of one compound, amitriptyline, to treat migraine in individual&#xD;
      patients. Taken together, the proposed research will provide substantial insights into basic&#xD;
      mechanisms supporting and regulating EA and can provide a foundation for mechanism-based&#xD;
      individualized choice of therapy that may benefit all chronic pain patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2011</start_date>
  <completion_date type="Actual">November 6, 2017</completion_date>
  <primary_completion_date type="Actual">November 6, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic response to the analgesic drugs</measure>
    <time_frame>2 month</time_frame>
    <description>The level of pain relief</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Duloxetine will be given in a daily dose of 30 mg for 5 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doluxetine</intervention_name>
    <description>30 mg/d</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>treatment</arm_group_label>
    <other_name>duloxetine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>suger pill 30mg/d</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>treatment</arm_group_label>
    <other_name>sugar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients diagnosed with migraine based on the International Headache Society (IHS)&#xD;
             criteria 1 that have &gt;4 attacks/month, both with and without aura&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients receiving any migraine preventive treatment during last 3 months or prior&#xD;
             treatment with amytriptiline&#xD;
&#xD;
          -  other chronic pain conditions&#xD;
&#xD;
          -  psychiatric, other neurological diseases, language barrier or cognitive dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rambam health care campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>d_yarnitsky</investigator_full_name>
    <investigator_title>Head of Neurology Department</investigator_title>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>pain</keyword>
  <keyword>CPM</keyword>
  <keyword>offset analgesia</keyword>
  <keyword>fMRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

